PE20191482A1 - Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii - Google Patents

Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii

Info

Publication number
PE20191482A1
PE20191482A1 PE2019001866A PE2019001866A PE20191482A1 PE 20191482 A1 PE20191482 A1 PE 20191482A1 PE 2019001866 A PE2019001866 A PE 2019001866A PE 2019001866 A PE2019001866 A PE 2019001866A PE 20191482 A1 PE20191482 A1 PE 20191482A1
Authority
PE
Peru
Prior art keywords
prognosis
gastric cancer
predict
patients
benefit
Prior art date
Application number
PE2019001866A
Other languages
English (en)
Inventor
Jae Ho Cheong
Sung Hoon Noh
Yong Min Huh
Hyun Ki Kim
Original Assignee
Novomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomics Co Ltd filed Critical Novomics Co Ltd
Publication of PE20191482A1 publication Critical patent/PE20191482A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a un sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio II y III, y se desarrolla un algoritmo que puede predecir el pronostico y la respuesta a quimioterapia usando resultados de analisis cuantitativo de niveles de expresion de ARNm de un grupo de genes marcadores relacionados con el pronostico o la respuesta a quimioterapia y un grupo de genes de referencia en cancer gastrico avanzado, y puede usarse como informacion complementaria para determinar un metodo para tratar un paciente con cancer gastrico
PE2019001866A 2017-03-14 2017-08-11 Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii PE20191482A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170032027 2017-03-14
PCT/KR2017/008781 WO2018169145A1 (ko) 2017-03-14 2017-08-11 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템

Publications (1)

Publication Number Publication Date
PE20191482A1 true PE20191482A1 (es) 2019-10-18

Family

ID=63523198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001866A PE20191482A1 (es) 2017-03-14 2017-08-11 Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii

Country Status (17)

Country Link
US (1) US11732304B2 (es)
EP (1) EP3517624B1 (es)
JP (1) JP6864089B2 (es)
KR (2) KR101966642B1 (es)
CN (1) CN110168106B (es)
AU (1) AU2017403899B2 (es)
BR (1) BR112019019022A2 (es)
CA (1) CA3055735C (es)
CL (1) CL2019002633A1 (es)
CO (1) CO2019011359A2 (es)
IL (1) IL269256A (es)
MX (1) MX2019011017A (es)
NZ (1) NZ756580A (es)
PE (1) PE20191482A1 (es)
RU (1) RU2737449C1 (es)
UA (1) UA125590C2 (es)
WO (1) WO2018169145A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3517624B1 (en) 2017-03-14 2024-10-02 Novomics Co., Ltd. System for predicting post-surgery prognosis or anticancer drug compatibility of advanced gastric cancer patients
KR101940657B1 (ko) * 2017-04-24 2019-01-21 (주) 노보믹스 위암의 생물학적 특성에 기반한 군 구분 및 예후 예측 시스템
WO2020226333A1 (ko) * 2019-05-03 2020-11-12 주식회사 디시젠 암 예후 예측방법 및 이의 조성물
KR102324294B1 (ko) * 2019-11-19 2021-11-11 서울대학교산학협력단 상피성 난소암 예후 예측 방법 및 장치
KR102811608B1 (ko) 2020-11-20 2025-05-21 주식회사 레피다인 간암의 예후 예측을 위한 정보 제공 방법
KR102462097B1 (ko) * 2020-12-30 2022-11-02 국립암센터 삼중사중극자 다중반응 모니터링 기반 암 표적치료제 효능 예측
CN113462773A (zh) * 2021-05-19 2021-10-01 山东大学 一种预测胃癌患者生存风险、免疫治疗响应和细胞焦亡诱导剂适用性的标志物及其应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用
KR102865138B1 (ko) * 2022-06-14 2025-09-29 연세대학교 산학협력단 높은 sfrp4의 발현을 보이는 암의 치료방법
WO2025127193A1 (ko) * 2023-12-13 2025-06-19 연세대학교 산학협력단 높은 sfrp4의 발현을 보이는 암의 치료방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404431C (en) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
JPWO2005007846A1 (ja) 2003-04-25 2006-08-31 財団法人癌研究会 腫瘍細胞の抗癌剤に対する感受性を判定する方法
KR20080006315A (ko) * 2006-07-12 2008-01-16 삼성전자주식회사 전기 영동 장치 및 그의 제조 방법
WO2008078969A1 (en) 2006-12-27 2008-07-03 Snu R&Db Foundation Data processing, analysis method of gene expression data to identify endogenous reference genes
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
PL2653546T3 (pl) 2010-12-13 2019-06-28 Samsung Life Public Welfare Foundation Marker do ustalenia rokowania raka żołądka i sposób ustalenia rokowania raka żołądka
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
KR101504817B1 (ko) 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
EP3517624B1 (en) 2017-03-14 2024-10-02 Novomics Co., Ltd. System for predicting post-surgery prognosis or anticancer drug compatibility of advanced gastric cancer patients

Also Published As

Publication number Publication date
EP3517624C0 (en) 2024-10-02
KR102069043B1 (ko) 2020-01-22
CN110168106A (zh) 2019-08-23
EP3517624B1 (en) 2024-10-02
NZ756580A (en) 2022-01-28
CA3055735A1 (en) 2018-09-20
KR20190024923A (ko) 2019-03-08
US11732304B2 (en) 2023-08-22
JP2019537436A (ja) 2019-12-26
KR20180105036A (ko) 2018-09-27
EP3517624A4 (en) 2020-04-29
CO2019011359A2 (es) 2019-10-31
CN110168106B (zh) 2024-02-20
CL2019002633A1 (es) 2020-04-03
RU2737449C1 (ru) 2020-11-30
AU2017403899A1 (en) 2019-09-19
AU2017403899B2 (en) 2021-12-09
JP6864089B2 (ja) 2021-04-21
BR112019019022A2 (pt) 2020-04-22
IL269256A (en) 2019-11-28
KR101966642B1 (ko) 2019-04-09
UA125590C2 (uk) 2022-04-27
US20190284637A1 (en) 2019-09-19
WO2018169145A1 (ko) 2018-09-20
MX2019011017A (es) 2020-01-20
CA3055735C (en) 2021-12-14
EP3517624A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
PE20191482A1 (es) Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii
CL2020001730A1 (es) Método para el tratamiento de cáncer. (divisional solicitud 201702728)
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018011491A (es) Disposiciones de secuencia y secuencias para presentacion de neoepitopos.
MX2016003245A (es) Calreticulina mutante para la diagnosis de malignidades mieloides.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
CL2015002126A1 (es) Sistemas y métodos para soporte de decisión clínica.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
BR112015030627A2 (pt) marcadores biológicos úteis na imunoterapia contra o câncer
CL2015002807A1 (es) Terapia de combinación
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
MX2018004586A (es) Terapia de combinacion para tratar tumores malignos.
MX2014011116A (es) Tratamiento de cancer con inhibidores de tor cinasa.
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2020006297A (es) Variantes de cd19.
BR112018007304A2 (pt) terapia de combinação para tratamento de malignidades
MX2019010150A (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5.
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
EA201991091A1 (ru) Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы